The Safety and Efficacy of Lorcaserin in the Management of Obesity

References

• . Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of obesity in the United States, 2009–2010. NCHS Data Brief. 2012;(82):1–8
   Google Scholar
• . Golden J. FDA 2007 Draft Guidance for Industry: Developing Products for Weight Management. Draft presented at: Endocrinologic and Metabolic Drugs Advisory Committee Meeting; March 28. 2012; Silver Spring, MD. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM299133.pdf. Accessed October 27, 2012
   Google Scholar
• . Finkelstein EA, Trogdon JG, Cohen JW, Dietz W. Annual medical spending attributable to obesity: payer-and service-specific estimates. Health Aff (Millwood). 2009;28(5):w822–w831
   PubMed Web of Science ®Google Scholar
• . LeBlanc E, O'Conner E, Whitlock EP, Patnode C, Kapka T. Screening for and management of obesity and overweight in adults. http://www.ncbi.nlm.nih.gov/books/NBK65294/pdf/TOC.pdf. Published October 2011. Accessed October 24, 2012
   Google Scholar
• . Stein CJ, Colditz GA. The epidemic of obesity. J Clin Endocrinol Metab. 2004;89(6):2522–2525
   PubMed Web of Science ®Google Scholar
• . de Wit L, Luppino F, van Straten A, Penninx B, Zitman F, Cuijpers P. Depression and obesity: a meta-analysis of community-based studies. Psychiatry Res. 2010;178(2):230–235
   PubMed Web of Science ®Google Scholar
• . Luppino FS, de Wit LM, Bouvy PF, . Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry. 2010;67(3):220–229
   PubMed Web of Science ®Google Scholar
• . Jia H, Lubetkin EI. The impact of obesity on health-related quality-of-life in the general adult US population. J Public Health (Oxf). 2005;27(2):156–164
   PubMed Web of Science ®Google Scholar
• . , Prospective Studies CollaborationWhitlock G, Lewington S, Sherliker P, Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. The Lancet. 2009;373(9669):1083–1096
   PubMed Web of Science ®Google Scholar
• . Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA. 2013;309(1):71–82
   PubMed Web of Science ®Google Scholar
• . Wing RR, Lang W, Wadden TA, ; LOOK AHEAD Research Group. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011;34(7):1481–1486
   PubMed Web of Science ®Google Scholar
• . Van Gaal LF, Mertens IL, Ballaux D. What is the relationship between risk factor reduction and degree of weight loss? Eur Heart J Suppl. 2005;7( suppl L):L21–L26
   Web of Science ®Google Scholar
• . Gregg EW, Chen H, Wagenknecht LE, ; LOOK AHEAD Research Group. Association of an intensive lifestyle intervention with remission of type 2 diabetes. JAMA. 2012;308(23):2489–2496
   PubMed Web of Science ®Google Scholar
• . Weight loss does not lower heart disease risk from type 2 diabetes [news release]. Bethesda, MD: National Institutes of Health; October 19, 2012. http://www.nih.gov/news/health/oct2012/niddk-19.htm. Accessed December 13, 2012
   Google Scholar
• . No authors listed. Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Arch Intern Med. 1998;158(17):1855–1867
   PubMedGoogle Scholar
• . Klok MD, Jakobsdottir S, Drent ML. The role of leptin and ghrelin in the regulation of food intake and body weight in humans: a review. Obes Rev. 2007;8(1):21–34
   PubMed Web of Science ®Google Scholar
• . Zhang X, Qi Q, Zhang C, . FTO genotype and 2-year change in body composition and fat distribution in response to weight-loss diets: the POUNDS LOST Trial. Diabetes. 2012;61(11):3005–3011
   PubMed Web of Science ®Google Scholar
• . Weinsier RL, Hunter GR, Heini AF, Goran MI, Sell SM. The etiology of obesity: relative contribution of metabolic factors, diet, and physical activity. Am J Med. 1998;105(2):145–150
   PubMed Web of Science ®Google Scholar
• . Alemany M, Remesar X, Fernandez-Lopez JA. Drug strategies for the treatment of obesity. IDrugs. 2003;6(6):566–572
   PubMedGoogle Scholar
• . Moyer VA; U.S. Preventative Services Task Force. Screening for and management of obesity in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157(5):373–378
   PubMed Web of Science ®Google Scholar
• . Snow V, Barry P, Fitterman N, Qaseem A, Weiss K; Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2005;142(7):525–531
   PubMed Web of Science ®Google Scholar
• . Logue J, Thompson L, Romanes F, Wilson DC, Thompson J, Sattar N; Guideline Development Group. Management of obesity: summary of SIGN guideline. BMJ. 2010;340:c154
   PubMed Web of Science ®Google Scholar
• . National Institute for Health and Clinical Excellence. Obesity. CG43, 2006. http://www.nice.org.uk/nicemedia/pdf/CG43NICEGuideline.pdf. Accessed December 13, 2012
   Google Scholar
• . Belviq [package insert]. Zofingen, Switzerland: Arena Pharmaceuticals, Inc; 2012
   Google Scholar
• . Thomsen WJ, Grottick AJ, Menzaghi F, . Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization. J Pharmacol Exp Ther. 2008;325(2):577–587
   PubMed Web of Science ®Google Scholar
• . Smith BM, Smith JM, Tsai JH, . Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity. J Med Chem. 2008;51(2):305–313
   PubMedGoogle Scholar
• . Roth BL. Drugs and valvular heart disease. N Engl J Med. 2007;356(1):6–9
   PubMed Web of Science ®Google Scholar
• . Rich S, Rubin L, Walker AM, Schneeweiss S, Abenhaim L. Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension. Chest. 2000;117(3):870–874
   PubMedGoogle Scholar
• . Arena Pharmaceuticals, Inc. FDA Briefing Document: Lorcaserin Hydrochloride, http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM303200.pdf. Accessed October 20, 2012
   Google Scholar
• . FDA issues complete response letter for lorcaserin new drug application [news release]. San Diego, CA: Arena Pharmaceuticals, Inc; October 23, 2010. http://invest.arenapharm.com/releasedetail.cfm?ReleaseID=521977. Accessed December 26, 2012
   Google Scholar
• . No authors listed. Energy and protein requirements. Report of a joint FAO/WHO/UNU expert consultation. World Health Organ Tech Rep Ser. 1985;724:1–206
   PubMedGoogle Scholar
• . Smith SR, Weissman NJ, Anderson CM, ; Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010;363(3):245–256
   PubMed Web of Science ®Google Scholar
• . Fidler MC, Sanchez M, Raether B, ; BLOSSOM Clinical Trial Group. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab. 2011;96(10):3067–3077
   PubMed Web of Science ®Google Scholar
• . Centers for Disease Control and Prevention (CDC). Prevalence of overweight and obesity among adults with diagnosed diabetes-United States, 1988–1994 and 1999–2002. MMWR Morb Mortal Wkly Rep. 2004;53(45):1066–1068
   PubMedGoogle Scholar
• . Sluik D, Boeing H, Montonen J, . Associations between general and abdominal adiposity and mortality in individuals with diabetes mellitus. Am J Epidemiol. 2011;174(1):22–34
   PubMedGoogle Scholar
• . Klein S, Sheard NF, Pi-Sunyer X, ; American Diabetes Association. North American Association for the Study of Obesity, American Society for Clinical Nutrition. Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies. A statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the American Society for Clinical Nutrition. Am J Clin Nutr. 2004;80(2):257–263
   PubMedGoogle Scholar
• . O'Neil PM, Smith SR, Weissman NJ, . Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring). 2012;20(7):1426–1436
   PubMed Web of Science ®Google Scholar
• . Arena Pharmaceuticals, Inc. FDA briefing document: NDA 22529, Lorcaserin (lorcaserin hydrochloride) tablets, 10 mg. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM225631.pdf. Accessed December 26, 2012
   Google Scholar
• . Shram MJ, Schoedel KA, Bartlett C, Shazer RL, Anderson CM, Sellers EM. Evaluation of the abuse potential of lorcaserin, a serotonin 2C (5-HT2C) receptor agonist, in recreational polydrug users. Clin Pharmacol Ther. 2011;89(5):683–692
   PubMed Web of Science ®Google Scholar
• . James WP, Caterson ID, Coutinho W, ; SCOUT Investigators. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010;363(10):905–917
   PubMed Web of Science ®Google Scholar
• . Kernan WN, Viscoli CM, Brass LM, . Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med. 2000;343(25):1826–1832
   PubMed Web of Science ®Google Scholar
• . Sam AH, Salem V, Ghatei MA. Rimonabant: from RIO to ban. J Obes. 2011;2011:432607
   PubMedGoogle Scholar
• . Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev. 2004;(3):CD004094
   Google Scholar
• . FDA drug safety communication: completed safety review of Xenical/Alii (orlistat) and severe liver injury [news release]. Silver Spring, MD: U.S. Food and Drug Administration; May 26, 2010. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetylnformationforPatientsandProviders/ucm213038.htm. Accessed April 16, 2013
   Google Scholar
• . Weir MA, Beyea MM, Gomes T, . Orlistat and acute kidney injury: an analysis of 953 patients. Arch Intern Med. 2011;171(7):703–704
   PubMed Web of Science ®Google Scholar
• . Hiatt WR, Thomas A, Goldfine AB. What cost weight loss? Circulation. 2012;125(9):1171–1177
   PubMedGoogle Scholar
• . Vivus, Inc. Qsymia (phentermine and topiramate extended-release) capsules: risk evaluation and mitigation strategy (REMS). http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetylnformationforPatientsandProviders/UCM312598.pdf. Accessed April 16, 2013
   Google Scholar
• . Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med. 2013;173(7):534–539
   PubMed Web of Science ®Google Scholar
• . FDA drug safety communication: FDA investigating reports of possible increased risk of pancreatitis and pre-cancerous findings of the pancreas from incretin mimetic drugs for type 2 diabetes. Silver Spring, MD: U.S. Food and Drug Administration; March 14, 2013. http://www.fda.gov/Drugs/DrugSafety/ucm343187.htm. Accessed April 17, 2013
   Google Scholar